 |
(3S)-3-[(2S)-2-({N-[2-tert-butyl)phenyl]carbamoyl}carbonylamino) propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanoci acid |
|---|---|
| Trade Name | |
| Orphan Indication | Patients undergoing solid organ transplantation |
| USA Market Approval | USA |
| USA Designation Date | 2003-08-19 00:00:00 |
| Sponsor | Pfizer Global Research and Development;50 Pequot Avenue;New London, Connecticut, 06320 |
